Sanofi, the multinational pharmaceutical company, is involved in numerous strategic moves to shore up growth and innovation. Recently, the company paid
€50M to SK bioscience as a pediatric pneumococcal vaccine progressed to
phase 3. It also purchased the China rights for aficamten and initiated a phase-3 trial for PCV21. In collaboration with Orano, Sanofi is working on next-generation radioligand medicines, and the CEO has warned businesses to avoid 'AI washing'. These activities come against the backdrop of ongoing
China-EU trade tensions. The company has struck a €300M deal with Orano and is moving its SK Bio-partnered pneumococcal shot into phase 3. Sanofi is said to be in discussions to sell a 50% stake in its consumer health business and is close to finalizing its terms of sale according to French government sources. It has also agreed to make
insulin pens available at $1 each. Significant milestones have been reached in two programs with
Exscientia. Sanofi's decision to exercise environmental responsibility and support the
decarbonization of healthcare systems also represents its forward-thinking approach to sustainable business practices.
Sanofi News Analytics from Mon, 04 Mar 2024 12:03:23 GMT to Tue, 24 Dec 2024 17:00:00 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 2
